Trial · NCT02176382

Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

NCT02176382, Phase 4, Completed, Massachusetts General Hospital; results first posted 2021-01-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Denosumab and Teriparatide Study (DATA-HD and DATA-EX). Trials, record NCT02176382. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02176382

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
NCT number: NCT02176382
Status: Completed
Phases: Phase 4
Enrollment: 76 participants, actual
Lead sponsor: Massachusetts General Hospital
Conditions: Postmenopausal Osteoporosis
Interventions: denosumab, teriparatide, Zoledronic acid
First posted: 2014-06-27
Last updated: 2021-02-09
Results first posted: 2021-01-22

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percent Change From Baseline in Spine Bone Mineral Density by Dual X-ray Absorptiometry (DXA)	Baseline and 42 months

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percent Change From Baseline in Spine Bone Mineral Density by Dual X-ray Absorptiometry (DXA)	Baseline and 42 months	Population includes those who completed a month 42 visit.	percent change in BMD	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Percent Change From Baseline in Spine Bone Mineral Density by Dual X-ray Absorptiometry (DXA)	Standard Dose Teriparatide		7.69	Standard Deviation 4.66	percent change in BMD
Percent Change From Baseline in Spine Bone Mineral Density by Dual X-ray Absorptiometry (DXA)	High Dose Teriparatide		12.70	Standard Deviation 5.54	percent change in BMD

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
DATA-HD Study	STARTED	Standard Dose Teriparatide	39
DATA-HD Study	STARTED	High Dose Teriparatide	37
DATA-HD Study	COMPLETED	Standard Dose Teriparatide	31
DATA-HD Study	COMPLETED	High Dose Teriparatide	29
DATA-HD Study	NOT COMPLETED	Standard Dose Teriparatide	8
DATA-HD Study	NOT COMPLETED	High Dose Teriparatide	8
DATA-HD Extension	STARTED	Standard Dose Teriparatide	27
DATA-HD Extension	STARTED	High Dose Teriparatide	26
DATA-HD Extension	COMPLETED	Standard Dose Teriparatide	26
DATA-HD Extension	COMPLETED	High Dose Teriparatide	26

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events26

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	back pain	Musculoskeletal and connective tissue disorders	Standard Dose Teriparatide	0	39
other	back pain	Musculoskeletal and connective tissue disorders	High Dose Teriparatide	2	37
serious	wrist fracture	Musculoskeletal and connective tissue disorders	Standard Dose Teriparatide	2	39
serious	wrist fracture	Musculoskeletal and connective tissue disorders	High Dose Teriparatide	1	37
serious	anal cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Standard Dose Teriparatide	0	39
serious	anal cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	High Dose Teriparatide	1	37
serious	breast cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Standard Dose Teriparatide	2	39
serious	breast cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	High Dose Teriparatide	0	37
serious	clavicle fracture	Musculoskeletal and connective tissue disorders	Standard Dose Teriparatide	1	39
serious	clavicle fracture	Musculoskeletal and connective tissue disorders	High Dose Teriparatide	0	37

1 to 10 of 26Source ClinicalTrials.gov

See all 26 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Standard Dose Teriparatide	0	39
Total, all-cause mortality	High Dose Teriparatide	0	37
Total, other adverse events	Standard Dose Teriparatide	0	39
Total, other adverse events	High Dose Teriparatide	2	37
Total, serious adverse events	Standard Dose Teriparatide	9	39
Total, serious adverse events	High Dose Teriparatide	2	37

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
31447409	RESULT	PubMed
31674641	BACKGROUND	PubMed
32790196	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Standard Dose Teriparatide vs High Dose Teriparatide: deaths from any cause	Trial comparisons
Standard Dose Teriparatide vs High Dose Teriparatide: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02176382

GET https://conductscience.org/api/trials/v1/NCT02176382/events?page=2

API reference For AI assistants